Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Brain Imaging Behav. 2017 Dec;11(6):1652–1663. doi: 10.1007/s11682-016-9608-4

Table 1.

Demographic Characteristics and Treatment History

Patients
(n=18)
Controls
(n=18)
Handedness (R/L) 18/0 17/1
Mean Education (SD) 15.6 (3.8) 15.9 (1.3)
Mean Est.VIQ 109 (8.6) 111 (8.1)
Age at study entry
 Mean (SD) 56.1 (8.2) 56.2 (9.1)
 Median (range) 57 (39–69) 59 (35–67)
Age at diagnosis
 Mean (SD) 55.3 (8.2) N/A
 Median (range) 56.5 (38–68) N/A
Diagnosis
 Ovarian 15 N/A
 Fallopian Tube 2 N/A
 Peritoneal 1 N/A
Disease Stage
 I 1 N/A
 II 0 N/A
 III 13 N/A
 IV 4 N/A
Chemotherapy regimen
 Paclitaxel, Carboplatin 12 N/A
 Paclitaxel, Cisplatin 4 N/A
 Paclitaxel, Cisplatin, Carboplatin 2 N/A
Mode of chemo administration
 IV 10 N/A
 IV/IP 8 N/A
Number of cycles completed
 Mean (SD) 6.3 (0.9) N/A
 Median (range) 6 (4–8) N/A
Time since chemo completion (days)
 Mean (SD) 81 (21) N/A
 Median (range) 79.5 (28–119) N/A
Menopausal at diagnosis (Y/N) 11/7 N/A
Menopausal at study entry (Y/N) 18/0 13/5

SD= standard deviation; Est.VIQ= Estimated Verbal IQ (NAART (Blair and Spreen 1989), or Barona Index (Barona et al. 1984); IV= intravenous; IP=intraperitoneal